Records containing: Recurrent Ovarian Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-03Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2026-03-27Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study
-
CLINICAL_TRIALS study record update · 2026-03-25A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
-
CLINICAL_TRIALS study record update · 2026-03-19Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2026-03-06A Single-Arm, Exploratory, Multicenter Study Evaluating Iparomlimab/Tuvonralimab Combined With Standard Chemotherapy Followed by Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-02-09Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2026-02-04Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2026-01-27Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF): A Phase III Randomized Controlled Trial of an Intervention Targeting Traumatic Stress in Patients With Advanced Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2025-12-08Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine Cancer
-
CLINICAL_TRIALS study record update · 2025-12-03A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
-
CLINICAL_TRIALS study record update · 2025-06-24A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 Combination Treatment in Subjects With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-06-19Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2025-04-30A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
-
CLINICAL_TRIALS study record update · 2025-04-06A Pilot Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Patients With Relapsed EOC After Treatment With PARPi
-
CLINICAL_TRIALS study record update · 2025-03-17A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
-
CLINICAL_TRIALS study record update · 2025-03-12An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2025-02-12Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Chosen by Cancer Stem Cell Chemosensitivity Testing in the Management of Patients With Recurrent Platinum-Resistant or -Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
-
CLINICAL_TRIALS study record update · 2024-04-11A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2023-10-06Delving Into the Patterns of Patient Engagement and Trends in Participation Within Recurrent Ovarian Cancer Clinical Trials
-
CLINICAL_TRIALS study record update · 2023-08-14A Phase I, Multi-center Study to Determine the Effect of Fluzoparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, Repaglinide and Bupropion in Patients With Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2023-04-19The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab in Maintenance Treatment for Platinum-Sensitive Recurrent Ovarian Cancer
-
CLINICAL_TRIALS study record update · 2023-04-18Signal TrAnsduction Pathway Activity Analysis in OVarian cancER
-
CLINICAL_TRIALS study record update · 2023-04-07A Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission
-
CLINICAL_TRIALS study record update · 2023-03-24Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
-
CLINICAL_TRIALS study record update · 2022-09-19Phase I Evaluation of Lenvatinib and Weekly Paclitaxel in Patients With Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer